Terms ending in 2039
Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,499,357 | Method and System for Transmission of Susi in the NAS Procedure In force · High confidence | AbbVie Deutschland GmbH & Co. KG | In force | High confidence | |
| US 10,508,113 | Inhibitors of Tyrosine Kinase 2 Mediated Signaling In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 10,954,202 | Protein Tyrosine Phosphatase Inhibitors and Methods of Use Thereof In force · High confidence | Calico Life Sciences LLC | In force | High confidence | |
| US D1,034,191 | Container Cap In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,542,239 | Elagolix Sodium Compositions and Processes In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,293,927 | Screening Methods for Parp Modulators In force · High confidence | AbbVie Biotechnology Ltd. | In force | High confidence | |
| US 11,149,043 | Prodrug Modulators of the Integrated Stress Pathway In force · Medium confidence | Calico Life Sciences LLC | In force | Medium confidence | |
| US 12,083,227 | Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis In force · Medium confidence | Neurocrine Biosciences, Inc. | In force | Medium confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by AbbVie Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.